Progesterone is contraindicated in patients with a history of stroke
Postmenopausal hormone therapy containing progesterone (with or without estrogen) should not be used in women with a prior cerebrovascular accident. This is a Class III recommendation with Level A evidence from the American Heart Association/American Stroke Association guidelines 1.
Evidence Base
The FDA drug label explicitly lists progesterone as contraindicated in patients with "active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions" 2. This contraindication is absolute and applies regardless of the clinical context for progesterone use.
Key Clinical Trial Data
Multiple large randomized controlled trials demonstrate harm:
Women's Health Initiative (WHI): Estrogen plus progestin increased stroke risk by 44% (HR 1.44,95% CI 1.09-1.90) in postmenopausal women 1. Estrogen alone showed similar increased risk (HR 1.53,95% CI 1.16-2.02) 1.
Women's Estrogen for Stroke Trial (WEST): Among 664 women with prior stroke or TIA, estradiol therapy resulted in higher risk of fatal stroke (HR 2.9,95% CI 0.9-9.0) 1. Women who had recurrent strokes while on hormone therapy were less likely to recover 1.
Heart and Estrogen/Progestin Replacement Study (HERS): No cardiovascular benefit was demonstrated, with no reduction in stroke risk among 2,763 postmenopausal women with heart disease 1.
Timing Does Not Matter
The "window of opportunity" hypothesis—that younger perimenopausal women might benefit from hormone therapy—has been definitively refuted. The Nurses' Health Study showed increased stroke risk was not associated with timing of hormone therapy initiation 1. In the WHI trial, stroke risk remained elevated regardless of years since menopause when therapy was started 1.
Clinical Decision-Making Algorithm
For any woman with prior stroke or TIA:
- Do not initiate progesterone-containing hormone therapy for any indication
- If already taking progesterone/hormone therapy when stroke occurs: discontinue immediately
- Alternative approaches for specific indications:
- For menopausal symptoms: non-hormonal options (SSRIs, gabapentin, lifestyle modifications)
- For endometrial protection: if estrogen is absolutely required (rare), consider alternative progestins with lower thrombotic risk, though this remains controversial
- For contraception in reproductive-age women: discuss stroke risk factors and consider progestin-only methods with extreme caution, or non-hormonal alternatives
Important Caveats
Pregnancy Context
The guidelines do address progesterone use in pregnant women with prior stroke, but this refers to anticoagulation strategies, not progesterone hormone therapy 1. For pregnant women with stroke/TIA and high-risk conditions (hypercoagulable states, mechanical valves), heparin-based anticoagulation is recommended—not progesterone therapy.
Experimental Stroke Treatment
While preclinical studies suggested progesterone might be neuroprotective after acute stroke 3, 4, 5, 6, clinical translation has failed. The evidence for progesterone as acute stroke treatment remains experimental and is not approved for clinical use. Moreover, meta-analysis of animal data revealed progesterone increased mortality in experimental stroke, particularly in young ovariectomized females 3.
Peanut Allergy Warning
Progesterone capsules contain peanut oil and are absolutely contraindicated in patients with peanut allergy 2.
Risk-Benefit Analysis
The absolute contraindication exists because:
- Mortality risk: Increased fatal stroke risk (HR 2.9) in women with prior cerebrovascular disease 1
- Recurrence risk: 44% increased risk of any stroke in primary prevention trials 1
- Recovery impairment: Worse neurological outcomes after recurrent stroke in hormone-treated patients 1
- No offsetting benefit: No cardiovascular or cerebrovascular protection demonstrated 1
The evidence is unequivocal: progesterone-containing hormone therapy increases stroke risk and worsens outcomes in women with prior cerebrovascular events, making it an absolute contraindication in this population.